​

Rallybio (RLYB) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChart

RLYB Stock Rating

Rallybio stock's rating consensus is Buy, based on 8 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 4 Buy (50.00%), 4 Hold (50.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 8 0 4 4 Strong Sell Sell Hold Buy Strong Buy

RLYB Price Target Upside V Benchmarks

TypeNameUpside
StockRallybio-
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts---
Avg Price Target---
Last Closing Price$0.62$0.62$0.62
Upside/Downside---
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Oct, 25-13--4
Sep, 25-13--4
Aug, 25-13--4
Jul, 25-13--4
Jun, 25-13--4
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Oct 01, 2024H.C. WainwrightBuyBuyhold
Sep 03, 2024H.C. WainwrightBuyBuyhold
Feb 22, 2022JMP SecuritiesMarket Outperforminitialise

Financial Forecast

EPS Forecast

$-3 $-2 $-1 $0 $1 $2 $3 $4 $5 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-1.84$-1.33----
Avg Forecast$-1.79$-1.42$-1.32$-2.73$0.19$4.64
High Forecast$-1.69$-1.40$-1.15$-2.73$0.19$4.64
Low Forecast$-1.85$-1.44$-1.48$-2.73$0.19$4.64
Surprise %2.79%-6.34%----

Revenue Forecast

$50M $120M $190M $260M $330M $400M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported-$636.00K----
Avg Forecast-$673.75K$305.00K-$87.90M$388.10M
High Forecast-$673.75K$305.00K-$87.90M$388.10M
Low Forecast-$673.75K$305.00K-$87.90M$388.10M
Surprise %--5.60%----

Net Income Forecast

$-150M $-80M $-10M $60M $130M $200M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-74.56M$-57.77M----
Avg Forecast$-74.56M$-57.44M$-49.20M$-110.42M$7.69M$187.68M
High Forecast$-68.46M$-56.58M$-46.60M$-110.42M$7.69M$187.68M
Low Forecast$-74.94M$-58.29M$-59.85M$-110.42M$7.69M$187.68M
Surprise %-0.59%----

RLYB Forecast FAQ

Is Rallybio stock a buy?

Rallybio stock has a consensus rating of Buy, based on 8 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 4 Buy, 4 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Rallybio is a favorable investment for most analysts.

What is Rallybio's price target?

Rallybio's price target, set by 8 Wall Street analysts, averages - over the next 12 months. The price target range spans from - at the low end to - at the high end, suggesting a potential 0% change from the previous closing price of $0.62.

How does Rallybio stock forecast compare to its benchmarks?

Rallybio's stock forecast shows a 0% downside, underperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Rallybio over the past three months?

  • October 2025: 0% Strong Buy, 25.00% Buy, 75.00% Hold, 0% Sell, 0% Strong Sell.
  • September 2025: 0% Strong Buy, 25.00% Buy, 75.00% Hold, 0% Sell, 0% Strong Sell.
  • August 2025: 0% Strong Buy, 25.00% Buy, 75.00% Hold, 0% Sell, 0% Strong Sell.

What is Rallybio’s EPS forecast?

Rallybio's average annual EPS forecast for its fiscal year ending in December 2025 is $-1.32, marking a -0.75% decrease from the reported $-1.33 in 2024. Estimates for the following years are $-2.73 in 2026, $0.19 in 2027, and $4.64 in 2028.

What is Rallybio’s revenue forecast?

Rallybio's average annual revenue forecast for its fiscal year ending in December 2025 is $305K, reflecting a -52.04% decrease from the reported $636K in 2024. The forecast for 2026 is $0, followed by $87.9M for 2027, and $388.1M for 2028.

What is Rallybio’s net income forecast?

Rallybio's net income forecast for the fiscal year ending in December 2025 stands at $-49.203M, representing a -14.84% decrease from the reported $-57.775M in 2024. Projections indicate $-110M in 2026, $7.69M in 2027, and $187.68M in 2028.